The stock of AtriCure Inc. (NASDAQ:ATRC) is a huge mover today! The stock increased 16.35% or $2.49 during the last trading session, hitting $17.68. About 1.18 million shares traded hands or 369.67% up from the average. AtriCure Inc. (NASDAQ:ATRC) has declined 6.69% since March 28, 2016 and is downtrending. It has underperformed by 11.40% the S&P500.
The move comes after 9 months positive chart setup for the $541.58M company. It was reported on Oct, 28 by Barchart.com. We have $22.98 PT which if reached, will make NASDAQ:ATRC worth $162.47M more.
AtriCure Inc. (NASDAQ:ATRC) Ratings Coverage
Out of 7 analysts covering Atricure Inc. (NASDAQ:ATRC), 6 rate it a “Buy”, 1 “Sell”, while 0 “Hold”. This means 86% are positive. Atricure Inc. has been the topic of 13 analyst reports since July 30, 2015 according to StockzIntelligence Inc. The stock of AtriCure Inc. (NASDAQ:ATRC) earned “Sell” rating by UBS on Friday, August 5. BTIG Research initiated AtriCure Inc. (NASDAQ:ATRC) rating on Friday, August 7. BTIG Research has “Buy” rating and $34 price target. UBS initiated the stock with “Sell” rating in Tuesday, September 22 report. Needham maintained it with “Buy” rating and $32 target price in Tuesday, August 4 report. The stock of AtriCure Inc. (NASDAQ:ATRC) has “Outperform” rating given on Tuesday, March 29 by Northland Capital. As per Tuesday, October 6, the company rating was maintained by Needham. The firm earned “Buy” rating on Wednesday, October 28 by Needham. The company was maintained on Friday, August 5 by Stifel Nicolaus. The firm has “Buy” rating by Canaccord Genuity given on Tuesday, October 6. The rating was maintained by Needham on Wednesday, July 29 with “Buy”.
According to Zacks Investment Research, “AtriCure, Inc. is a medical device company focused on developing, manufacturing and selling innovative surgical devices to create precise lesions, or scars, in soft tissues. Medical journals have described the adoption by leading cardiothoracic surgeons of the AtriCure, Inc. bipolar ablation system as a standard treatment alternative during open-heart surgical procedures to safely, rapidly and reliably create lesions in cardiac, or heart, tissue to block the abnormal electrical impulses that cause atrial fibrillation, a quivering of the upper chambers of the heart.”
Insitutional Activity: The institutional sentiment decreased to 0.96 in Q2 2016. Its down 0.19, from 1.15 in 2016Q1. The ratio dropped, as 15 funds sold all AtriCure Inc. shares owned while 31 reduced positions. 5 funds bought stakes while 39 increased positions. They now own 24.21 million shares or 10.01% less from 26.90 million shares in 2016Q1.
Dafna, a California-based fund reported 513,946 shares. Paradigm Cap Management Ny holds 0.57% or 329,225 shares in its portfolio. Waddell Reed Financial Inc, a Kansas-based fund reported 267,800 shares. Moreover, Secor Cap Lp has 0.09% invested in AtriCure Inc. (NASDAQ:ATRC) for 53,017 shares. Aqr Mngmt Limited Co holds 0% of its portfolio in AtriCure Inc. (NASDAQ:ATRC) for 10,047 shares. Moreover, Blair William & Il has 0.01% invested in AtriCure Inc. (NASDAQ:ATRC) for 100,185 shares. First Light Asset Limited Co holds 922,590 shares or 6.04% of its portfolio. Blackrock Japan Ltd, a Japan-based fund reported 633 shares. Ardsley Advisory Prtn holds 0.02% of its portfolio in AtriCure Inc. (NASDAQ:ATRC) for 10,000 shares. Metropolitan Life Insur Ny has 23,721 shares for 0% of their US portfolio. Raymond James And has 0% invested in the company for 30,000 shares. Rothschild Cap Prtn Ltd last reported 1.82% of its portfolio in the stock. Blackrock Inc has 0% invested in the company for 3,389 shares. California State Teachers Retirement System has invested 0% of its portfolio in AtriCure Inc. (NASDAQ:ATRC). Moreover, Citigroup Inc has 0% invested in AtriCure Inc. (NASDAQ:ATRC) for 2,319 shares.
Insider Transactions: Since August 16, 2016, the stock had 0 buys, and 2 selling transactions for $171,580 net activity. 6,000 shares were sold by Krell Elizabeth D, worth $95,580.
Another recent and important AtriCure Inc. (NASDAQ:ATRC) news was published by Businesswire.com which published an article titled: “AtriCure Announces Approval for the AtriClip in Japan” on January 19, 2016.
ATRC Company Profile
AtriCure, Inc., incorporated on October 31, 2000, is a medical device firm providing atrial fibrillation (Afib) solutions. The Company’s segment develops, makes, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. The Firm has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures. The Firm offers various minimally invasive ablation devices and access tools to facilitate less invasive cardiac and thoracic surgery. The Company’s cryoICE cryosurgery product line offers various cryoablation devices. The Company’s AtriClip Left Atrial Appendage Exclusion System is designed to occlude the heart’s left atrial appendage (LAA). The Company’s products are utilized by cardiothoracic surgeons during both open-heart and minimally invasive procedures, either on a concomitant or sole-therapy basis. The Company’s Isolator Synergy System, which includes its Isolator Synergy clamps, radio frequency (RF) generator and related switchbox, provides treatment for persistent and long-standing persistent Afib concomitant to other open-heart surgical procedures, such as coronary artery bypass grafting and/or valve replacement or repair. The Firm has two primary product lines for cardiac tissue ablation, which include Radio Frequency Ablation Devices and cryoICE Cryoablation System, and a product line for left atrial appendage exclusion.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.